Commerce ministry in its latest data has showed that with the government focusing on boosting domestic manufacturing of pharmaceutical products, India's medicine and antibiotics exports have started gaining significant market share in the US. India is the third largest import source of 'medicine put up for retail sale' for the US. The top two are Ireland and Switzerland. In 2023, the country exported these medicines worth $9 billion as against $7.33 billion in 2022.
According to the data, with this increase in the shipments, India's share went up to 13.1 per cent in 2023 from 10.08 per cent in 2022. Share of the top exporter Ireland fell to 13.85 per cent in 2023 from 17.18 per cent in 2022 because its sales in the US went down to $9.5 billion in 2023 from $12.5 billion in 2022. The second biggest exporter Switzerland also saw its share decline to 13.7 per cent last year from 17.4 per cent in 2022. Similarly, India has increased its share among exporters of antibiotics in the Italian market. It is ranked 10th in that market by increasing its share to 2.12 per cent in 2023 from 0.96 per cent in 2022.
The data further indicated that in value terms, the country's antibiotics exports to Italy stood at $23.34 million in 2023 as against $11.48 million in 2022. Further the data showed that India's competitiveness is growing in the Magnetic Resonance Imaging (MRI) apparatus market of Germany. In 2023, the country made a small gain by increasing its export share in Germany to 1.7 per cent from 0.45 per cent in 2022. In value terms, India exported these MRI machines worth $13.02 million last year as against $2.93 million in 2022. India is the sixth largest exporter of MRI apparatus, whereas the UK is the leader with exports of $460 million.
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: